A Phase 2 interventional study of Paxalisib (GDC-0084) in Glioblastoma, Adult, sponsored by Kazia Therapeutics Limited. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-24.
Sponsored by Kazia Therapeutics Limited · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,302 studies in Glioblastoma with a site in United States — 194 open to participants now, 323 under way, 16 of them phase 3. Glioblastoma · United States.
Among the 1,302 studies in Glioblastoma with a site in United States, this one is the 601st largest by enrollment of the 1,155 interventional ones that give a count, is one of 72 that started in 2018, is one of 396 in phase 2, and was the 849th registered.
2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
Browse Glioblastoma studies →194 of the 1,302 studies in Glioblastoma with a site in United States are open now. Recruiting first, the newest first:
Macarena De La Fuente, MD · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Alpheus Medical, Inc. · Sites in United States
Ages 18–80
Beijing Inno Medicine Co., Ltd. · Sites in United States, China
Ages 18–70
City of Hope Medical Center · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 340 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,302 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 671 · Phase 2 592 · Phase 3 55 · Phase 4 4
First in 1979; this study’s year is marked. 72 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 36 across 1,756 interventional studies indexed under Glioblastoma.
Median enrollment 33 across the 1,155 interventional studies, 60 across the 79 observational. Of the 883 that completed or were terminated, 344 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
321 of 1,302 have an industry lead sponsor. The 10 most frequent:
Kazia Therapeutics Limited is the lead sponsor of 5 studies on the registry; none are open to participants now.
Kazia Therapeutics Limited has 1 study filed under Glioblastoma — fewer than ten, so there is no comparison to draw.
104 of the studies in Glioblastoma with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05271240Phase 3Northwell HealthRepeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM | 2027-04-01 |
| NCT03743662Memorial Sloan Kettering Cancer CenterNivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma | 2026-11 |
| NCT04574856University of Michigan Rogel Cancer CenterMultiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma | 2026-11-19 |
| NCT02704858Neonc Technologies, Inc.Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma | 2026-11-30 |
| NCT05781321Mayo ClinicShort Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study | 2026-11-30 |
Add all 104 to your calendar (.ics) → With an account.
Among the 1,302 studies in Glioblastoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This protocol has a 2-part design:
This phase 2 study is an open-label, multicenter, dose-escalation and expansion study to assess the safety, tolerability, recommended phase 2 dose (RP2D), pharmacokinetics (PK) and clinical activity of paxalisib in patients with newly-diagnosed glioblastoma (GBM) with unmethylated MGMT promoter status as adjuvant therapy following surgical resection and initial chemoradiation with temozolomide (TMZ).
Stage 1 Dose-Escalation and Maximum Tolerated Dose The dose-escalation portion of the study (Stage 1) will use a standard "3 + 3" design to determine the MTD for QD dosing.
Approximately 6 - 12 patients with newly diagnosed GBM will be enrolled in Stage 1.
The MTD for QD dosing will be determined. The initial dose level for QD dosing will be 60 mg (Dose Level 0). This dose is based on the phase 1 findings outlined in the rationale in the protocol, adding 1 dose level to test for a potential MTD increase.
Dose-escalation will occur in Stage 1:
Decisions regarding dose-escalation and selection will be made by a Cohort Review Committee (CRC).
All AEs, including DLTs, will be reported, with severity assessed according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03.
After determination of the MTD, patients continue to receive their protocol-assigned dose levels of paxalisib until progression of their disease or an unacceptable toxicity, whichever occurs first.
Stage 2 Expansion stage (2) of the study will be a two-arm, randomized, open-label expansion study to further characterize the safety, tolerability and PK of paxalisib as well as to provide a preliminary assessment of single-agent activity of paxalisib in patients with GBM. Approximately 20 patients will be enrolled in the expansion cohort in 2 treatment arms (10 per am) to examine the PK of paxalisib in fed and fasted-conditions, according to the defined study eligibility criteria.
Stage 2 of the study will be initiated with recruitment of new patients as soon as the MTD has been determined.
Patients enrolled in Stage 2 may continue the study at the dose allocated until disease progression or unacceptable toxicity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must meet all the following inclusion criteria to be eligible for enrollment into the study:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This is an open-label study. Patients in Stage 1 will be enrolled and sequentially assigned to a dose cohort. The initial cohort will receive an oral dose of 60 mg paxalisib QD (4 x 15 mg capsules). Patients of future dose cohorts will receive paxalisib at increasing levels with 15 mg steps until a dose-limiting toxicity occurs (DLT) occurs. The dose level where \<1/3 of the patients exhibit a DLT will be determined the Maximum Tolerated Dose (MTD). In stage 1, dose escalation will occur for QD dosing. In stage 2, the expansion phase, patients will receive doses of oral paxalisib at the MTD in stage 1, until disease progression or an unacceptable toxicity, whichever occurs first. Patients will be randomized in a 1:1 ratio to fed or fasted schedules.
Drug: Paxalisib (GDC-0084)
Patients will be dosed orally with paxalisib (GDC-0084) capsules (15-mg each) at the dose and schedule to which they are assigned.
Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)
A DLT was defined as a Grade 3 or 4 toxicity occurring within the DLT assessment window and assessed to be probably or possibly related to paxalisib. DLTs were graded using the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. CTCAE Grade 3 is a severe adverse event (AE) and Grade 4 is a life-threatening or disabling AE. DLTs were collected to determine the maximum tolerated dose (MTD), which was defined as the dose level below the dose at which less than 33% of participants experienced a DLT.
Time frame: Cycle 1, Days 1-28
Incidence of Treatment-emergent Adverse Events (TEAEs)
The toxicity assessments were made according to the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. A TEAE is any AE occurring or worsening on/after the first study drug dose and within 28 days after the last dose date. The number of participants with Grade 1 to 5 TEAEs are reported here. Specific Adverse Event terms are provided in the Adverse Event module
Time frame: 24 months
Incidence of Serious Adverse Events (SAEs)
An SAE is any AE that meets one or more of the following: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; requires intervention to prevent permanent impairment or damage. Specific AE terms are provided in the Adverse Event module
Time frame: 24 months
Incidence of Treatment-emergent Grade 3/4 Treatment Emergent Adverse Events
Treatment emergent Adverse Events were graded using the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. CTCAE Grade 3 is a severe adverse event (AE) and Grade 4 is a life-threatening or disabling AE. Participants are counted at the highest grade TEAE that they experienced.
Time frame: 24 months
Number of Participants Who Experienced a Change in Electrocardiogram (ECG) Parameter QTc
A change in ECG parameter QTc was defined as an increase of QTc to a value ≥ 500 msec or a change from baseline of at least 60 msec.
Time frame: 24 months
Number of Participants Who Experienced a Change Left Ventricular Ejection Fraction
A change in left ventricular ejection fraction (LVEF) was defined as a reduction in LVEF to a value of ≤ 45% from baseline.
Time frame: 24 months
Progression-free Survival Interval Using Using mRANO Criteria/Investigator Review.
Progression-free survival is defined as the duration of time from start of treatment to time of progression or death, whichever comes first.
Time frame: 24 months
Overall Survival Using RANO Criteria.
Overall survival is defined as the duration of time from the first day of study treatment until the date of death.
Time frame: 24 months
Pharmacokinetics of Paxalisib as Area Under the Curve From Time 0 to Last Measurable Time Point (AUC0-last) and/or Area Under the Curve From Time 0 to Infinity (AUC0-inf).
Blood samples were obtained and plasma concentrations were determined using a validated high-pressure liquid chromatography method. Samples were obtained: prior to the initial dose on Cycle 1 Day 1 and then at 30 minutes, and at 1, 2, 3, 4, 6 8 and 24 hours post dose.
Time frame: 24 hours
Maximum Observed Plasma Concentration of Paxalisib (Cmax)
Blood samples were obtained and plasma concentrations were determined using a validated high-pressure liquid chromatography method. Samples were obtained: prior to the initial dose on Cycle 1 Day 1 and then at 30 minutes, and at 1, 2, 3, 4, 6 8 and 24 hours post dose.
Time frame: 24 hours
Pharmacokinetics of Paxalisib as Time to Reach Cmax (Tmax).
Blood samples were obtained and plasma concentrations were determined using a validated high-pressure liquid chromatography method. Samples were obtained: prior to the initial dose on Cycle 1 Day 1 and then at 30 minutes, and at 1, 2, 3, 4, 6 8 and 24 hours post dose.
Time frame: 24 hours
Change in FDG-PET Uptake in Response to Paxalisib in Patients With Measurable Disease.
FDG-PET imaging was obtained using a stand-alone PET or combined PET/computed tomography (CT) scanner, or hybrid PET/MRI systems and the and mean FDG-PET standard uptake value quantified
Time frame: Cycle 1, Day 3
Change in FDG-PET Uptake in Response to Paxalisib in Patients With Measurable Disease
FDG-PET imaging was obtained using a stand-alone PET or combined PET/computed tomography (CT) scanner, or hybrid PET/MRI systems and the and mean FDG-PET standard uptake value quantified
Time frame: Cycle 1, Day 7
Disease Control Rate.
Response to treatment was assessed by MRI using the response assessment in neuro-oncology (RANO) criteria based on the assessment of the MRI scan and clinical features. The DCR is defined as the proportion of patients achieving a confirmed best overall response of complete response (CR; disappearance of all enhancing disease, clinically stable/improved), partial response (PR; 50% or more decrease in measurable enhancing lesions, clinically stable/improved), or stable disease (SD, does not qualify for CR or PR, does not qualify for disease progression, clinically stable). To be assigned a status of CR, PR or SD patients need to have two consecutive assessments of CR, PR or SD. To be assigned a best overall response of SD patients must have a minimum duration of SD of at least 6 weeks.
Time frame: 24 months
Open-label, multicenter dose-escalation study with expansion. This study comprised 2 stages, Stage 1 (dose escalation) and Stage 2 (dose expansion and fed/fasted investigation)
| Milestone | Dose-escalating Cohort 1: Paxalisib 60mg | Dose-escalating Cohort 2: Paxalisib 75 mg | Expansion Cohort: Paxalisib 60mg (Fed) | Expansion Cohort: Paxalisib 60mg (Fasted) |
|---|---|---|---|---|
| Started | 3 | 6 | 10 | 11 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 3 | 6 | 10 | 11 |
| Withdrew: Adverse event | 1 | 0 | 0 | 1 |
| Withdrew: Death | 2 | 4 | 8 | 8 |
| Withdrew: Patient decision | 0 | 2 | 2 | 2 |
A DLT was defined as a Grade 3 or 4 toxicity occurring within the DLT assessment window and assessed to be probably or possibly related to paxalisib. DLTs were graded using the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. CTCAE Grade 3 is a severe adverse event (AE) and Grade 4 is a life-threatening or disabling AE. DLTs were collected to determine the maximum tolerated dose (MTD), which was defined as the dose level below the dose at which less than 33% of participants experienced a DLT.
| Participants | Dose-escalating Cohort 1: Paxalisib 60mg | Dose-escalating Cohort 2: Paxalisib 75 mg |
|---|---|---|
| Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) | 0 | 2 |
The toxicity assessments were made according to the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. A TEAE is any AE occurring or worsening on/after the first study drug dose and within 28 days after the last dose date. The number of participants with Grade 1 to 5 TEAEs are reported here. Specific Adverse Event terms are provided in the Adverse Event module
| Participants | Dose-escalating Cohort 1: Paxalisib 60mg | Dose-escalating Cohort 2: Paxalisib 75 mg | Expansion Cohort: Paxalisib 60mg (Fed) | Expansion Cohort: Paxalisib 60mg (Fasted) |
|---|---|---|---|---|
| Incidence of Treatment-emergent Adverse Events (TEAEs) | 3 | 6 | 10 | 11 |
An SAE is any AE that meets one or more of the following: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; requires intervention to prevent permanent impairment or damage. Specific AE terms are provided in the Adverse Event module
| Participants | Dose-escalating Cohort 1: Paxalisib 60mg | Dose-escalating Cohort 2: Paxalisib 75 mg | Expansion Cohort: Paxalisib 60mg (Fed) | Expansion Cohort: Paxalisib 60mg (Fasted) |
|---|---|---|---|---|
| Incidence of Serious Adverse Events (SAEs) | 2 | 5 | 6 | 5 |
Treatment emergent Adverse Events were graded using the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. CTCAE Grade 3 is a severe adverse event (AE) and Grade 4 is a life-threatening or disabling AE. Participants are counted at the highest grade TEAE that they experienced.
| Participants | Dose-escalating Cohort 1: Paxalisib 60mg | Dose-escalating Cohort 2: Paxalisib 75 mg | Expansion Cohort: Paxalisib 60mg (Fed) | Expansion Cohort: Paxalisib 60mg (Fasted) |
|---|---|---|---|---|
| Grade 1 or 2 | 0 | 0 | 1 | 0 |
| Grade 3 | 3 | 3 | 9 | 10 |
| Grade 4 | 0 | 3 | 0 | 1 |
A change in ECG parameter QTc was defined as an increase of QTc to a value ≥ 500 msec or a change from baseline of at least 60 msec.
| Participants | Dose-escalating Cohort 1: Paxalisib 60mg | Dose-escalating Cohort 2: Paxalisib 75 mg | Expansion Cohort: Paxalisib 60mg (Fed) | Expansion Cohort: Paxalisib 60mg (Fasted) |
|---|---|---|---|---|
| Number of Participants Who Experienced a Change in Electrocardiogram (ECG) Parameter QTc | 0 | 0 | 0 | 0 |
A change in left ventricular ejection fraction (LVEF) was defined as a reduction in LVEF to a value of ≤ 45% from baseline.
| Participants | Dose-escalating Cohort 1: Paxalisib 60mg | Dose-escalating Cohort 2: Paxalisib 75 mg | Expansion Cohort: Paxalisib 60mg (Fed) | Expansion Cohort: Paxalisib 60mg (Fasted) |
|---|---|---|---|---|
| Number of Participants Who Experienced a Change Left Ventricular Ejection Fraction | 0 | 0 | 0 | 1 |
Progression-free survival is defined as the duration of time from start of treatment to time of progression or death, whichever comes first.
| Months | Dose-escalating Cohort 1: Paxalisib 60mg | Dose-escalating Cohort 2: Paxalisib 75 mg | Expansion Cohort: Paxalisib 60mg (Fed) | Expansion Cohort: Paxalisib 60mg (Fasted) |
|---|---|---|---|---|
| Progression-free Survival Interval Using Using mRANO Criteria/Investigator Review. | 14.5 (3.3 to 25.7) | 4.7 (1.8 to 27.4) | 7.0 (1.0 to 13.2) | 5.5 (2.0 to 11.8) |
Overall survival is defined as the duration of time from the first day of study treatment until the date of death.
| Months | Dose-escalating Cohort 1: Paxalisib 60mg | Dose-escalating Cohort 2: Paxalisib 75 mg | Expansion Cohort: Paxalisib 60mg (Fed) | Expansion Cohort: Paxalisib 60mg (Fasted) |
|---|---|---|---|---|
| Overall Survival Using RANO Criteria. | 20.1 (14.4 to 25.7) | 11.8 (4.4 to 37.5) | 12.0 (7.6 to 17.6) | 9.8 (2.0 to 15.1) |
Blood samples were obtained and plasma concentrations were determined using a validated high-pressure liquid chromatography method. Samples were obtained: prior to the initial dose on Cycle 1 Day 1 and then at 30 minutes, and at 1, 2, 3, 4, 6 8 and 24 hours post dose.
| ng/mL*h | Dose-escalating Cohort 1: Paxalisib 60mg | Dose-escalating Cohort 2: Paxalisib 75 mg | Expansion Cohort: Paxalisib 60mg (Fed) | Expansion Cohort: Paxalisib 60mg (Fasted) |
|---|---|---|---|---|
| Pharmacokinetics of Paxalisib as Area Under the Curve From Time 0 to Last Measurable Time Point (AUC0-last) and/or Area Under the Curve From Time 0 to Infinity (AUC0-inf). | 1180 ± 36.6 | 1120 ± 91.4 | 2190 ± 34.5 | 1640 ± 67.1 |
Blood samples were obtained and plasma concentrations were determined using a validated high-pressure liquid chromatography method. Samples were obtained: prior to the initial dose on Cycle 1 Day 1 and then at 30 minutes, and at 1, 2, 3, 4, 6 8 and 24 hours post dose.
| ng/mL | Dose-escalating Cohort 1: Paxalisib 60mg | Dose-escalating Cohort 2: Paxalisib 75 mg | Expansion Cohort: Paxalisib 60mg (Fed) | Expansion Cohort: Paxalisib 60mg (Fasted) |
|---|---|---|---|---|
| Maximum Observed Plasma Concentration of Paxalisib (Cmax) | 174 ± 108 | 118 ± 67.4 | 176 ± 24.2 | 114 ± 44.2 |
Blood samples were obtained and plasma concentrations were determined using a validated high-pressure liquid chromatography method. Samples were obtained: prior to the initial dose on Cycle 1 Day 1 and then at 30 minutes, and at 1, 2, 3, 4, 6 8 and 24 hours post dose.
| Hours | Dose-escalating Cohort 1: Paxalisib 60mg | Dose-escalating Cohort 2: Paxalisib 75 mg | Expansion Cohort: Paxalisib 60mg (Fed) | Expansion Cohort: Paxalisib 60mg (Fasted) |
|---|---|---|---|---|
| Pharmacokinetics of Paxalisib as Time to Reach Cmax (Tmax). | 3.00 (2.00 to 5.42) | 2.50 (1.95 to 4.00) | 4.00 (2.80 to 8.00) | 3.93 (3.00 to 8.00) |
FDG-PET imaging was obtained using a stand-alone PET or combined PET/computed tomography (CT) scanner, or hybrid PET/MRI systems and the and mean FDG-PET standard uptake value quantified
| standardized uptake value | Expansion Cohort: Paxalisib 60mg (Fed) | Expansion Cohort: Paxalisib 60mg (Fasted) |
|---|---|---|
| Change in FDG-PET Uptake in Response to Paxalisib in Patients With Measurable Disease. | 0.036 ± 0.7523 | -0.442 ± 0.3517 |
FDG-PET imaging was obtained using a stand-alone PET or combined PET/computed tomography (CT) scanner, or hybrid PET/MRI systems and the and mean FDG-PET standard uptake value quantified
| standardized uptake value | Expansion Cohort: Paxalisib 60mg (Fed) | Expansion Cohort: Paxalisib 60mg (Fasted) |
|---|---|---|
| Change in FDG-PET Uptake in Response to Paxalisib in Patients With Measurable Disease | -0.366 ± 1.1814 | -0.432 ± 0.5963 |
Response to treatment was assessed by MRI using the response assessment in neuro-oncology (RANO) criteria based on the assessment of the MRI scan and clinical features. The DCR is defined as the proportion of patients achieving a confirmed best overall response of complete response (CR; disappearance of all enhancing disease, clinically stable/improved), partial response (PR; 50% or more decrease in measurable enhancing lesions, clinically stable/improved), or stable disease (SD, does not qualify for CR or PR, does not qualify for disease progression, clinically stable). To be assigned a status of CR, PR or SD patients need to have two consecutive assessments of CR, PR or SD. To be assigned a best overall response of SD patients must have a minimum duration of SD of at least 6 weeks.
| Participants | Dose-escalating Cohort 1: Paxalisib 60mg | Dose-escalating Cohort 2: Paxalisib 75 mg | Expansion Cohort: Paxalisib 60mg (Fed) | Expansion Cohort: Paxalisib 60mg (Fasted) |
|---|---|---|---|---|
| Disease Control Rate. | 3 | 4 | 8 | 9 |
Collected over 24 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose-escalating Cohort 1: Paxalisib 60mg | 2/3 (66.7%) | 2/3 (66.7%) | 3/3 (100%) |
| Dose-escalating Cohort 2: Paxalisib 75 mg | 4/6 (66.7%) | 5/6 (83.3%) | 6/6 (100%) |
| Expansion Cohort: Paxalisib 60mg (Fed) | 8/10 (80%) | 6/10 (60%) | 10/10 (100%) |
| Expansion Cohort: Paxalisib 60mg (Fasted) | 8/11 (72.7%) | 5/11 (45.5%) | 11/11 (100%) |
| Event | Dose-escalating Cohort 1: Paxalisib 60mg | Dose-escalating Cohort 2: Paxalisib 75 mg | Expansion Cohort: Paxalisib 60mg (Fed) | Expansion Cohort: Paxalisib 60mg (Fasted) |
|---|---|---|---|---|
| FatigueGeneral disorders | 1/3 | 0/6 | 0/10 | 1/11 |
| DehydrationMetabolism and nutrition disorders | 1/3 | 0/6 | 1/10 | 0/11 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/3 | 2/6 | 1/10 | 1/11 |
| Acute kidney injuryRenal and urinary disorders | 1/3 | 0/6 | 0/10 | 0/11 |
| Dermatitis exfoliativeSkin and subcutaneous tissue disorders | 1/3 | 0/6 | 0/10 | 0/11 |
| PneumoniaInfections and infestations | 0/3 | 0/6 | 2/10 | 0/11 |
| StomatitisGastrointestinal disorders | 0/3 | 1/6 | 1/10 | 0/11 |
| confusional statePsychiatric disorders | 0/3 | 1/6 | 1/10 | 0/11 |
| Status epilepticusNervous system disorders | 0/3 | 1/6 | 0/10 | 0/11 |
| Posterior reversible encephalopathy syndromeNervous system disorders | 0/3 | 1/6 | 0/10 | 0/11 |
| Event | Dose-escalating Cohort 1: Paxalisib 60mg | Dose-escalating Cohort 2: Paxalisib 75 mg | Expansion Cohort: Paxalisib 60mg (Fed) | Expansion Cohort: Paxalisib 60mg (Fasted) |
|---|---|---|---|---|
| FatigueGeneral disorders | 3/3 | 4/6 | 6/10 | 9/11 |
| HyperglycaemiaMetabolism and nutrition disorders | 1/3 | 5/6 | 3/10 | 4/11 |
| NauseaGastrointestinal disorders | 2/3 | 2/6 | 4/10 | 4/11 |
| VomitingGastrointestinal disorders | 2/3 | 1/6 | 1/10 | 3/11 |
| ConstipationGastrointestinal disorders | 2/3 | 0/6 | 0/10 | 1/11 |
| DehydrationMetabolism and nutrition disorders | 2/3 | 1/6 | 4/10 | 2/11 |
| Platelet count decreasedInvestigations | 2/3 | 4/6 | 2/10 | 1/11 |
| StomatitisGastrointestinal disorders | 1/3 | 3/6 | 6/10 | 4/11 |
| Decreased appetiteMetabolism and nutrition disorders | 1/3 | 2/6 | 5/10 | 6/11 |
| DiarrhoeaGastrointestinal disorders | 0/3 | 3/6 | 2/10 | 5/11 |
ITT population The intent-to-treat (ITT) population consisted of all patients who were enrolled in the study, whether in Stage 1 or Stage 2.
| Age, Continuous(years) | Dose-escalating Cohort 1: Paxalisib 60mg | Dose-escalating Cohort 2: Paxalisib 75 mg | Expansion Cohort: Paxalisib 60mg (Fed) | Expansion Cohort: Paxalisib 60mg (Fasted) | Total |
|---|---|---|---|---|---|
| Mean | 68 ± 15.72 | 56 ± 9.30 | 56 ± 12.51 | 59.5 ± 9.46 | 58.5 ± 11.16 |
| Sex: Female, Male(Participants) | Dose-escalating Cohort 1: Paxalisib 60mg | Dose-escalating Cohort 2: Paxalisib 75 mg | Expansion Cohort: Paxalisib 60mg (Fed) | Expansion Cohort: Paxalisib 60mg (Fasted) | Total |
|---|---|---|---|---|---|
| Female | 0 | 2 | 3 | 4 | 9 |
| Male | 3 | 4 | 7 | 7 | 21 |
| Ethnicity (NIH/OMB)(Participants) | Dose-escalating Cohort 1: Paxalisib 60mg | Dose-escalating Cohort 2: Paxalisib 75 mg | Expansion Cohort: Paxalisib 60mg (Fed) | Expansion Cohort: Paxalisib 60mg (Fasted) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 1 | 2 |
| Not Hispanic or Latino | 3 | 5 | 10 | 10 | 28 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Dose-escalating Cohort 1: Paxalisib 60mg | Dose-escalating Cohort 2: Paxalisib 75 mg | Expansion Cohort: Paxalisib 60mg (Fed) | Expansion Cohort: Paxalisib 60mg (Fasted) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 0 | 1 |
| White | 2 | 4 | 9 | 10 | 25 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 | 2 |
| Region of Enrollment(participants) | Dose-escalating Cohort 1: Paxalisib 60mg | Dose-escalating Cohort 2: Paxalisib 75 mg | Expansion Cohort: Paxalisib 60mg (Fed) | Expansion Cohort: Paxalisib 60mg (Fasted) | Total |
|---|---|---|---|---|---|
| United States | 3 | 6 | 10 | 11 | 30 |
| Time since diagnosis(months) | Dose-escalating Cohort 1: Paxalisib 60mg | Dose-escalating Cohort 2: Paxalisib 75 mg | Expansion Cohort: Paxalisib 60mg (Fed) | Expansion Cohort: Paxalisib 60mg (Fasted) | Total |
|---|---|---|---|---|---|
| Mean | 3.68 ± 0.553 | 4.33 ± 1.137 | 3.64 ± 0.358 | 3.56 ± 0.318 | 3.75 ± 0.637 |
| Type of surgery(Participants) | Dose-escalating Cohort 1: Paxalisib 60mg | Dose-escalating Cohort 2: Paxalisib 75 mg | Expansion Cohort: Paxalisib 60mg (Fed) | Expansion Cohort: Paxalisib 60mg (Fasted) | Total |
|---|---|---|---|---|---|
| Biopsy (Patients later had a complete resection) | 0 | 0 | 1 | 1 | 2 |
| Complete resection | 2 | 4 | 9 | 7 | 22 |
| Partial resection | 1 | 2 | 0 | 2 | 5 |
| Other (stereotactic biopsy) | 0 | 0 | 0 | 1 | 1 |
| Histological diagnosis(Participants) | Dose-escalating Cohort 1: Paxalisib 60mg | Dose-escalating Cohort 2: Paxalisib 75 mg | Expansion Cohort: Paxalisib 60mg (Fed) | Expansion Cohort: Paxalisib 60mg (Fasted) | Total |
|---|---|---|---|---|---|
| Count of participants | 3 | 6 | 10 | 11 | 30 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2018 to primary completion in Mar 2023, 58 months.
Results were first posted in Mar 2025, 1 year 11 months after primary completion.
Of 51 industry-sponsored phase 2 interventional studies under Glioblastoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 58. This study's 58 months is above that.
Counting every sponsor, half of 249 studies reached it within 55 months; a quarter within 40 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GDC-0084
Kazia Therapeutics Limited